Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen to Mine 4 Million Patient Records for Predictive Markers

This article has been corrected to note that Perlegen is a spinout of Affymetrix, not a subsidiary as previously reported.
 
NEW YORK (GenomeWeb News) – Perlegen Sciences said today it will work with an undisclosed electronic medical records company to search through data from four million patients for genetic markers that could help predict patient response to certain medical treatments.
 
Perlegen said it has reached an agreement under which it will have exclusive access to a database of US medical records, from which it will target patients who will be sought for DNA samples.
 
The EMR company will be paid subscription and program fees and milestone payments connected to the launch of any new diagnostic tests that result from the collaboration. Perlegen also said it will receive partial ownership in the EMR provider, the volume of which will be dependent on achieving certain revenue levels.
 
Perlegen, which is a spinout of Affymetrix, said it will work with the patients’ doctors to obtain the DNA samples in a way that is compliant with US privacy laws. That means that Perlegen “will never have access to specific patient identities, but instead will only receive de-identified patient records, which can then be re-identified only by participating healthcare institutions” in a manner that is consistent with US health insurance law.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.